Severity
Moderate
FDA Drug recall · Reported January 22, 2020
cGMP Deviations; released lots were manufactured under similar manufacturing conditions to a previously rejected OOS Lot.
Sun Pharmaceutical Industries, Inc. recalled Testosterone Cypionate for Injection, USP, 1,000 mg/10 mL (100 mg/mL), 10 mL Multiple Dos… - a moderate-severity action.
Testosterone Cypionate for Injection, USP, 1,000 mg/10 mL (100 mg/mL), 10 mL Multiple Dos… was recalled by Sun Pharmaceutical Industries, Inc. in January 22, 2020. Reason: cGMP Deviations; released lots were manufactured under similar manufacturing conditions to a previously rejec…. Check the official notice for the remedy. Verify recall #D-0787-2020 with the FDA Drug before acting.
The recall
Sun Pharmaceutical Industries, Inc. issued this moderate-severity FDA Drug recall-cGMP Deviations; released lots were manufactured under similar manufacturing conditions to a previously rejec….
Sourced from official FDA Drug enforcement records. Verify recall #D-0787-2020 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0787-2020) was formally reported on January 22, 2020, with the manufacturer initiating the action on January 14, 2020. It is classified under Moderate severity (Class II), with a current status of Terminated. Sun Pharmaceutical Industries, Inc. is listed as the recalling firm, operating out of Cranbury, NJ. The number of affected units is not disclosed in the agency filing, which is common for drug and food recalls where lot-level tracking supersedes unit counts.
The documented reason for this recall is: cGMP Deviations; released lots were manufactured under similar manufacturing conditions to a previously rejected OOS Lot. Distribution data in the federal record shows the product reached: Product was distributed throughout the United States.. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
Unknown
Related Recalls
6
5 from same agency
Testosterone Cypionate for Injection, USP, 1,000 mg/10 mL (100 mg/mL), 10 mL Multiple Dose Vial (NDC 62756-017-40), Rx only, Distributed by: Sun Pharmaceuticals, Inc., Cranbury, NJ, Manufactured by: Sun Pharmaceuticals, Industries, Ltd., Gujarat, India
cGMP Deviations; released lots were manufactured under similar manufacturing conditions to a previously rejected OOS Lot.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Terminated |
| Recall number | D-0787-2020 |
| Date reported | January 22, 2020 |
| Date initiated | January 14, 2020 |
| Recalling firm | Sun Pharmaceutical Industries, Inc. |
| Firm location | Cranbury, NJ |
| Affected scope | Not disclosed |
| Distribution | Product was distributed throughout the United States. |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported January 22, 2020. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.